VitalConnect is a leader in biosensor technology focused on ambulatory cardiac monitoring. Its proprietary biosensor streams eight vital signs and biometric parameters live over a seven-day wear period. The company leverages biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinical decision making and better health and economic outcomes. Its products are designed for use in both remote and in‑patient settings to deliver lower‑cost care and greater convenience for patients and providers. Four years after its commercial launch, VitalConnect reports commercial growth and plans to expand its commercial presence. The company closed $100 million in financing (equity and debt) to accelerate that expansion. VitalConnect develops wearable biosensors and a cloud/mobile platform (the VitalPatch) for real-time remote and in-hospital monitoring. The company leverages biomedical engineering, data analytics, chip design and software to support clinical decision-making and lower healthcare costs. VitalConnect has deployed hundreds of thousands of biosensors globally at institutions including Brigham and Women’s, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital‑Oxford University. The new funding will support a rapidly growing remote cardiac monitoring business and help advance partnerships with the largest U.S. hospital systems to provide remote patient monitoring in inpatient settings. VitalConnect reports revenue tripled from 2021 to 2022, is on track to nearly double revenue again in 2023, has seen significant EBITDA improvement, and expects to achieve profitability in 2024. VitalConnect is a leader in wearable biosensor technology, offering the VitalPatch for real-time remote and in-hospital monitoring. Founded in 2011 and based in San Jose, Calif., the company combines biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinical decision-making. Its devices have deployed hundreds of thousands of biosensors worldwide and are used in care facilities including Brigham and Women's, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital–Oxford University. Products target a broad range of inpatient and outpatient use cases such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect reports strong physician adoption and growth over the past 18 months since launch. The company plans to use new funding to accelerate its cardiac monitoring business and advance remote patient monitoring for heart failure, COPD, sepsis, and other conditions, strengthening commercial access to patients and providers. VitalConnect’s flagship product, the VitalPatch, enables real-time remote and in-hospital patient monitoring. The company combines biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinician decision-making. VitalConnect has deployed more than 200,000 patches worldwide and is used at institutions including Brigham and Women’s, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital–Oxford University. The company announced a $39 million growth financing to expand its commercial team, scale operations, and develop new products to drive top-line growth. The round was funded by EW Healthcare Partners alongside other new and existing investors, and EW Operating Partner Robert S. White joined VitalConnect’s board. VitalConnect’s products target inpatient and outpatient settings such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect develops the VitalPatch wearable biosensor and a software platform for wireless patient monitoring in hospitals and remote settings. The VitalPatch is a small, single-use Class II FDA-approved, band-aid-like device that continuously measures eight vital signs in real time. The company's software platform is already being implemented in select hospitals. Led by founder and CEO Nersi Nazari and launched in 2011, VitalConnect is focused on product development and broader clinical rollout. The company plans to use new funding to continue product development and to roll out the VitalConnect Platform and VitalPatch across hospitals and outpatient settings nationwide. The company has completed multiple funding rounds prior to the current Series C.

Total raised

$232M

Funding rounds

8

Latest round

Equity

Latest activity

Feb 2025